Statement Of Cash Flows [Abstract]

BerGenBio - Filing #2581090

Concept As at
2022-12-31
2022-01-01 to
2022-12-31
As at
2021-12-31
2021-01-01 to
2021-12-31
As at
2020-12-31
Statement of cash flows [abstract]
Cash flows from (used in) operating activities [abstract]
Cash flows from (used in) operating activities
288,231,000 NOK
303,340,000 NOK
Cash flows from (used in) investing activities [abstract]
Proceeds from sales of property, plant and equipment, classified as investing activities
299,000 NOK
Interest received, classified as investing activities
2,949,000 NOK
3,130,000 NOK
Cash flows from (used in) investing activities
3,248,000 NOK
3,130,000 NOK
Cash flows from (used in) financing activities [abstract]
Proceeds from issuing shares
3,218,000 NOK
16,629,000 NOK
Payments of lease liabilities, classified as financing activities
307,000 NOK
565,000 NOK
Cash flows from (used in) financing activities
2,904,000 NOK
15,995,000 NOK
Increase (decrease) in cash and cash equivalents before effect of exchange rate changes
282,080,000 NOK
284,216,000 NOK
Effect of exchange rate changes on cash and cash equivalents [abstract]
Effect of exchange rate changes on cash and cash equivalents
3,764,000 NOK
779,000 NOK
Cash and cash equivalents
150,803,000 NOK
436,646,000 NOK
721,641,000 NOK

Talk to a Data Expert

Have a question? We'll get back to you promptly.